IP Library Granted Patent US 11,426,465
Granted Patent B2
US 11,426,465 · App. 17/114,245 · Granted Aug 30, 2022

Hydrazinyl-indole compounds and methods for producing a conjugate

Inventors: Romas Alvydas Kudirka (El Cerrito, CA); Aaron Edward Albers (San Francisco, CA); Robyn M. Barfield (Emeryville, CA); David Rabuka (Kensington, CA)
Assignee: Redwiid Bioscience, Inc.
A61K47/545A61K47/64A61K47/6803A61K47/6851A61K47/6889A61K49/0041A61K49/0058G01N33/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,465
App. No.
17/114,245
Granted
Aug 30, 2022
Kind
B2
Abstract

The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

Claims (36)

1. A method of producing a conjugate, the method comprising:

combining in a reaction mixture:

(i) a compound of formula (IV):

wherein

Q 2 is Y 4 ;

Q 3 is —(CH 2 ) n NR 3 NHR 2 ;

n is 0 or 1;

R 2 and R 3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;

X 1 is C or N, wherein if X 1 is N, then Y 1 is absent;

X 2 , X 3 and X 4 are each C;

Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;

L is an optional linker; and

W 1 is selected from a drug and a detectable label; and

(ii) an antibody comprising a reactive group,

wherein the combining is under reaction conditions suitable to promote reaction between the compound and the reactive group of the antibody compound to form a conjugate; and

(iii) isolating the conjugate from the reaction mixture.

2. The method of claim 1 , wherein W 1 is the drug.

3. The method of claim 1 , wherein the reactive group comprises a reactive aldehyde group or a reactive ketone group.

4. The method of claim 1 , wherein the reaction mixture comprises water.

5. The method of claim 1 , wherein the reaction mixture has a pH of 7.

6. The method of claim 1 , wherein the reaction conditions are at a temperature of 37° C.

7. A pharmaceutical composition comprising:

a conjugate produced by the method of claim 1 ; and

a pharmaceutically acceptable excipient.

8. The method of claim 1 , wherein n is 1.

9. The method of claim 1 , wherein R 2 and R 3 are each independently selected from alkyl and substituted alkyl.

10. The method of claim 1 , wherein R 2 and R 3 are each methyl.

11. The method of claim 1 , wherein X 1 , X 2 , X 3 and X 4 are each C.

12. The method of claim 1 , wherein Y 1 , Y 2 , Y 3 and Y 4 are each H.

13. The method of claim 1 , wherein L is present and comprises a group selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl amino, alkylamide, substituted alkylamide, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

14. The method of claim 1 , wherein L is present and comprises a polymer.

15. The method of claim 14 , wherein the polymer is a polyethylene glycol.

16. The method of claim 1 , wherein the detectable label comprises a fluorophore.

17. The method of claim 2 , wherein the compound is a compound of formula (V):

18. The method of claim 2 , wherein the compound is a compound of formula (Va):

19. The method of claim 1 , wherein the antibody is an antibody specific for CD22.

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2021
From: KUDIRKA, ROMAS ALVYDAS; ALBERS, AARON EDWARD; BARFIELD, ROBYN M.; RABUKA, DAVID
To: REDWOOD BIOSCIENCE, INC.
Reel/Frame 055110/0867 →
Continuity (6)
Division 16392162 · Apr 23, 2019
Continuation 15799846 · Oct 31, 2017
Division 15057847 · Mar 1, 2016
Division 13794159 · Mar 11, 2013
Provisional Application 61727603 · Nov 16, 2012
Related Publication 20210162054A1 · Jun 3, 2021